UNITY Biotechnology Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Okay. Welcome back everybody to the next session of SVB Securities Healthcare Conference. I appreciate you joining us. I'm Marc Goodman, one of the biopharma analysts here. And we are lucky enough to have Unity Bio join us now. And we have Anirvan Ghosh, who is the CEO.
There are several companies focused on alternative therapies, the VEGF retinal diseases and Unity is one of them that we're very interested in carefully tracking what they're doing. And the data so far has been very interesting. And so I encourage everybody to really take a look at this very interesting story, very different. I'm going to turn it over to you, Anirvan, please walk through the story for us. And I think we may have some time for questions at the end. And if we don't, it's okay, it's up to you, go ahead.
All right. Thanks, Marc. I'm pleased to provide an update on our lead program, UBX1325, which we are developing for two major retinal indications. Before I go into my presentation, I just
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |